医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Genetron Health and InnoCare Team Up In Partnership To Accelerate the Development and Commercialization of Novel Drugs for Cancer Treatment

2020年02月22日 AM12:32
このエントリーをはてなブックマークに追加


 

BEIJING

Genetron Holding Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, has announced a strategic partnership with Beijing InnoCare Pharma Tech Co., Ltd. (“InnoCare”) to provide clinical trial genomic testing and companion diagnostics development services for InnoCare’s biomarker-driven oncology drug development.

Committed to advancing the research and development process and clinical utility of biopharmaceutical companies’ novel biomarker-driven oncology drug, Genetron Health has already formed partnerships with dozens of leading companies including AstraZeneca, Roche, Novartis, CStone Pharmaceuticals, Alphamab, Juventus Cell Therapy, EdiGene, etc.

Benchmarking global quality standards, Genetron Health has built a one-stop comprehensive genomic profiling platform to support drug research and development for multinational and local innovative biopharmaceutical companies and biomedical CRO partners. Genetron Health provides a range of services, including biomarker evaluation for molecularly targeted therapy and immuno-therapy, clinical trial enrolment and testing, companion diagnostics development and commercialization and joint-marketing post-drug approval.

  1. Clinical trial enrollment and testing: Genetron Health provides a seamless, integratedsolution covering clinical trial consulting and planning, GCP-complied molecular and immuno testing services based on its CAP and CLIA certificated laboratories, patient recruitment and enrollment, and data collection and analysis.
  2. Companion diagnostics development and commercialization: Genetron Health has a comprehensive NMPA-approved technology platform covering NGS, dPCR and qPCR for companion diagnostics development, a professional and experienced team for IVD product registration and innovative patented technologies such as the One-Step Seq Method. As a pioneer in the field of precision oncology in China, Genetron Health can provide customized and integrated diagnostic assay development and commercialization services to meet the needs of biopharmaceutical companies. For instance, in December 2019, Genetron health announced strategic partnership with CStone Pharmaceuticals on companion diagnostics and clinical trial testing.
  3. Early-stage R&D and real world study (RWS): Genetron Health has a large real-world cancer genomics database and proven research capabilities and technologies to provide powerful genomic testing services and data research support for early-stage R&D, biomarker development and RWS needs of biopharmaceutical companies, CROs, and research institutions.

About Genetron Health

Genetron Health is a leading and fast-growing precision oncology company in China that specializes in cancer molecular profiling. We harness advanced technologies in molecular biology and data science to transform cancer treatment. Driven by our mission to transform cancer treatment and prevention globally by driving technological innovation and accelerating the adoption of precision oncology medicine, we offer our products and services through three business units: diagnosis and monitoring, early screening, and development services. Genetron was founded in 2015 and is based in Beijing, China. For more information, please visit www.genetronhealth.com.

More information about InnoCare please visit http://www.innocarepharma.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200221005316/en/

CONTACT

Tao Yuan

E-mail: pr@genetronhealth.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease